Vance J C, Bart B J, Hansen R C, Reichman R C, McEwen C, Hatch K D, Berman B, Tanner D J
Arch Dermatol. 1986 Mar;122(3):272-7.
We conducted a multicenter double-blind study comparing human recombinant intralesional alpha-2 interferon (IFN) and placebo in 237 patients with the clinical diagnosis of condyloma acuminatum or verruca plantaris. A single wart on each patient was injected with 0.1 mL containing 10(6) IU of IFN, 10(5) IU of IFN, or placebo three times weekly for three weeks, and the response to treatment was followed up for 12 weeks. Among 91 of the 114 patients with condyloma acuminatum who completed the study, complete clearing of the treated wart occurred in 16 (53%) of 30 patients receiving 10(6) IU of IFN compared with six (19%) of 32 receiving 10(5) IU of IFN and four (14%) of 29 receiving placebo. In the group of 100 patients with plantar warts, there was no apparent benefit associated with interferon administration. Seven patients (3%) had treatment discontinued due to adverse reactions. Intralesional alpha-2 IFN is of benefit in the treatment of a single condyloma; its role in the treatment of multiple lesions remains to be clarified. Its role in the treatment of verruca plantaris, where no response was seen, also remains to be clarified.
我们进行了一项多中心双盲研究，比较人重组病灶内注射α-2干扰素（IFN）和安慰剂对237例临床诊断为尖锐湿疣或跖疣患者的疗效。对每位患者的单个疣体每周注射3次，每次注射含10⁶国际单位IFN的0.1毫升溶液、含10⁵国际单位IFN的0.1毫升溶液或安慰剂，共注射3周，并对治疗反应进行12周的随访。在114例完成研究的尖锐湿疣患者中，91例患者中，30例接受10⁶国际单位IFN治疗的患者中有16例（53%）治疗疣体完全清除，而32例接受10⁵国际单位IFN治疗的患者中有6例（19%），29例接受安慰剂治疗的患者中有4例（14%）。在100例跖疣患者组中，给予干扰素治疗未显示明显益处。7例患者（3%）因不良反应而停止治疗。病灶内注射α-2干扰素对单个尖锐湿疣的治疗有益；其在多个病灶治疗中的作用仍有待阐明。其在跖疣治疗中未见反应，其作用也有待阐明。
